Home › CRL's bottom line continues to be driven by biotech growth, CEO says
 

Keywords :   


CRL's bottom line continues to be driven by biotech growth, CEO says

2015-03-06 03:45:14| Biotech - Topix.net

For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday. The growth for CRL, which Foster called " an interesting phenomenon worth noting, " comes as biotech companies have become the drug discovery engines of Big Pharma.

Tags: line bottom says growth

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.12South Western Railway to be renationalised by Labour
03.12Woolchemy Develops Wool-Based ADL Materials
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
More »